Home
NewsNewsMochida Grants LG Chem Endometriosis Drug Licensing to develop and sell Dinagest that has an active ingredient, Dienogest, that halts endometrial cells from growing, offering a non-hormonal therapeutic option for women suffering from endometriosis.
Mochida Pharmaceutical, which is based in Japan, and LG Chem, which is based in South Korea, have made a deal to work together on Dinagest. Mochida sells Dinagest in Japan, where it is used to treat endometriosis as well as other conditions.
As part of the endometriosis drug licensing deal, Mochida has given LG Chem exclusive rights to develop and sell the product in South Korea and Thailand. LG Chem will get the necessary marketing approvals in each country and then make the product available to patients.
Dienogest, the active ingredient in Dinagest, is a progestin that stops the ovaries from working and halts endometrial cells from growing by selectively binding to the progesterone receptor.
Mochida introduced the product in Japan in 2008 and has been looking for ways to expand it into other countries. Mochida has also been working to grow its business operations around the world by 2031. As a result of these efforts, Mochida is moving forward with the product's first global expansion as part of this agreement.
For more than 30 years, LG Chem has been an expert in the research and production of hormone-based therapies for infertility treatment in the field of reproductive medicine. LG Chem continues to be a trusted partner in the field of reproductive medicine because it has high-quality products, does ongoing research and development, and is very dedicated to patients and doctors.
With Endometriosis Drug Licensing, Mochida has given LG Chem exclusive rights to develop and sell Dinagest. Apparently, both companies have worked together before on the biosimilars of etanercept and adalimumab. These products were subsequently released in Japan. Mochida and LG Chem want to get the product to patients in South Korea and Thailand and help them live better lives by way of this new agreement.
ARMS Embryo Watch offers time-lapse images of IVF embryos to patients by streaming each development stage and showing the output directly to the patient's device, enhancing transparency and emotional connection throughout the IVF journey.
Luna and Kindbody are redefining Intelligence in Fertility Care through a strategic partnership that integrates wearable biomarker tracking into clinical pathways. By capturing real-time physiological data, the collaboration enables personalised insights, enhances decision-making, and creates a more connected, data-driven fertility journey for patients and care providers alike.
The MOAA-Endorsed Bill for Fertility Challenges seeks to expand fertility care access for veterans by recognising infertility as a service-connected condition. By reducing barriers to IVF and treatment, the legislation addresses toxic exposure risks and aims to provide timely, equitable reproductive healthcare support for those who served.
Fairfax IVI expand donor sperm access through a strategic partnership that enhances availability, integrates donor services into fertility care, and supports diverse patient needs. With personalised guidance, genetic insights, and streamlined logistics, the collaboration aims to reduce barriers and deliver a more accessible, inclusive path to parenthood.
Sapyen and Avenues launch at-home fertility diagnostics, introducing a couple-first testing model in the UK. By integrating semen analysis and AMH testing into early care, this approach reduces clinic visits, accelerates diagnosis, and ensures balanced fertility evaluation, transforming how patients begin their reproductive health journey.
Nexpring Health has invested in May Health to accelerate the development of the Anavi™ System, a novel device designed to treat PCOS-Related Infertility. The technology aims to restore ovulation through a single office-based procedure, expanding treatment options for millions of women affected by polycystic ovary syndrome.
